Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human TRAIL in relapsed/refractory advanced NSCLC
CTR20161061Phase 3Active
- Sponsor
- Shanghai Gebaide Biotechnology Co., Ltd.
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulanermin in non-small cell lung cancer (NSCLC), sponsored by Shanghai Gebaide Biotechnology Co., Ltd.. Started Feb 2017; status: active.
02
Drugs
dulanermin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20161061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161061.